Figure 2

ARPV/ZIKV shows protective immunity at ≥ 10¹¹ genome copies (GC). Four-week-old C57BL/6 J mice (n = 6) were inoculated subcutaneously (s.c.) with the indicated agents or with saline (PBS) as shown in study schematic (a). All mice except PBS were challenged with ZIKV DakAr D 41524 s.c. with 2 × 10⁵ plaque forming units (PFU) or PBS at 30 days post immunization and monitored for 14 days post challenge for weight change and survival. Sera was collected at 1 week post immunization, and 2 weeks post immunization, 4 weeks post challenge respectively and ZIKV-specific Plaque Reduction Neutralizing Tests (PRNT₅₀) were done (b). Viremia was measured from sera collected on days 1–4 post challenge (c,d). Limit of detection is indicated by the dotted line. Data points represent mean values and error bars represent the standard deviation. Significance was determined by two-way ANOVA and mixed-effect analyses. Unless otherwise marked, asterisks indicate significance compared to healthy controls (PBS): not significant (ns), p ≤ 0.033 (*), p ≤ 0.002 (**), p ≤ 0.0002 (***) and p ≤ 0.0001 (****). Unless otherwise marked, there was no significant difference between PBS and ARPV/ZIKV groups.